NCT02411448 2026-01-16RELAYEli Lilly and CompanyPhase 3 Active not recruiting545 enrolled 24 charts 2 FDA
NCT04248829 2024-12-03Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)Yuhan CorporationPhase 3 Active not recruiting393 enrolled 13 charts